Safety, immunogenicity and efficacy of prime-Boost vaccination with chad63 and mva encoding me-trap against plasmodium falciparum infection in adults in senegal

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Mensah, Victorine A ^a   Gueye, Aly ^a   Ndiaye, Magatte ^a   Edwards, Nick J ^b   Wright, Danny ^b   Anagnostou, Nicholas A ^b   Syll, Massamba ^a   Ndaw, Amy ^a   Abiola, Annie ^a   Bliss, Carly ^b   Gomis, Jules François ^a   Petersen, Ines ^c   Ogwang, Caroline ^d   Dieye, Tandakha ^a   Viebig, Nicola K ^c   Lawrie, Alison M ^b   Roberts, Rachel ^b   Nicosia, Alfredo ^e,f   Faye, Babacar ^a   Gaye, Oumar ^a   Leroy, Odile ^c   Imoukhuede, Egeruan B ^b,c   Ewer, Katie J ^b   Bejon, Philip ^d   Hill, Adrian V S ^b   Cisse, Badara ^a,g   more..

^a UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c European Vaccine Initiative   (Germany)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e ReiThera ^*  (Italy)

^f CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; CHIMPANZEE ADENOVIRUS VACCINE; ERYTHROCYTE ANTIGEN; IMMUNOGLOBULIN G; MALARIA VACCINE; MODIFIED VACCINIA ANKARA VACCINE; MULTIPLE EPITOPE THROMBOSPONDIN RELATED ADHESION PROTEIN; RABIES VACCINE; UNCLASSIFIED DRUG; PROTOZOAL PROTEIN; THROMBOSPONDIN-RELATED ADHESIVE PROTEIN, PROTOZOAN;

ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CHILL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; FEVER; FOLLOW UP; GENERAL ASPECTS OF DISEASE; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALAISE; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PARASITEMIA; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SENEGAL; SINGLE BLIND PROCEDURE; SWELLING; T LYMPHOCYTE; TIME TO INFECTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TYPHOID FEVER; URBAN AREA; VACCINATION; ADVERSE EFFECTS; GENETICS; IMMUNOLOGY; MALARIA, FALCIPARUM; PATHOGENICITY; PLASMODIUM FALCIPARUM; PROCEDURES; SIMIAN VIRUS; VACCINIA VIRUS;

ADENOVIRUSES, SIMIAN; ADULT; ANTIMALARIALS; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PROTOZOAN PROTEINS; SENEGAL; VACCINATION; VACCINIA VIRUS;

EID: 85006399716     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0167951     Document Type: Article

References (32)

1. WHO (2013) World Malaria Report 2013. Geneva: World Health Organisation.
2. Ceesay SJ, Casals-Pascual C, Nwakanma DC, Walther M, Gomez-Escobar N, Fulford AJ, et al. (2010) Continued decline of malaria in The Gambia with implications for elimination. PLoS One 5: e12242. doi: 10.1371/journal.pone.0012242 PMID: 20805878
3. Noor AM, Kinyoki DK, Mundia CW, Kabaria CW, Mutua JW, Alegana VA, et al. (2014) The changing risk of Plasmodium falciparum malaria infection in Africa: 2000-10: a spatial and temporal analysis of transmission intensity. Lancet.
4. Das P, Horton R (2010) Malaria elimination: worthy, challenging, and just possible. Lancet 376: 1515-1517. doi: 10.1016/S0140-6736(10)61551-6 PMID: 21035845
5. Baird JK (2010) Eliminating malaria-all of them. Lancet 376: 1883-1885. doi: 10.1016/S0140-6736 (10)61494-8 PMID: 21035840
6. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. (2011) First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. The New England journal of medicine 365: 1863-1875. doi: 10.1056/NEJMoa1102287 PMID: 22007715
7. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359: 2521-2532. doi: 10.1056/ NEJMoa0807381 PMID: 19064627
8. Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Olivier A, et al. (2010) Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. PLoS One 5: e14090. doi: 10.1371/journal.pone.0014090 PMID: 21124768
9. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, et al. (2011) Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis 11: 102-109. doi: 10.1016/S1473-3099(10)70262-0 PMID: 21237715
10. RTSS Clinical trials partnership (2012) A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. The New England journal of medicine.
11. Rts SCTP (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386: 31-45. doi: 10.1016/S0140-6736(15)60721-8 PMID: 25913272
12. Duncan CJ, Hill AV (2011) What is the efficacy of the RTS,S malaria vaccine? BMJ 343: d7728. doi: 10. 1136/bmj.d7728 PMID: 22167776
13. Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, et al. (2012) ChAd63-MVAvectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol Ther 20: 2355-2368. doi: 10.1038/mt.2012.223 PMID: 23089736
14. Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, et al. (2013) Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS One 8: e57726. doi: 10.1371/journal.pone.0057726 PMID: 23526949
15. Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, et al. (2015) Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. J Infect Dis 211: 1076-1086. doi: 10.1093/infdis/jiu579 PMID: 25336730
16. Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, et al. (2013) Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nature communications 4: 2836. doi: 10.1038/ncomms3836 PMID: 24284865
17. Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, et al. (2014) Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. Mol Ther 22: 1992-2003. doi: 10.1038/mt.2014.109 PMID: 24930599
18. Imoukhuede EB, Andrews L, Milligan P, Berthoud T, Bojang K, Nwakanma D, et al. (2007) Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. The American journal of tropical medicine and hygiene 76: 486-493. PMID: 17360872
19. Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, et al. (2015) Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med 7: 286re285.
20. Machault V, Gadiaga L, Vignolles C, Jarjaval F, Bouzid S, Sokhna C, et al. (2009) Highly focused anopheline breeding sites and malaria transmission in Dakar. Malar J 8: 138. doi: 10.1186/1475-2875-8-138 PMID: 19552809
21. O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, et al. (2012) Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. The Journal of infectious diseases 205: 772-781. doi: 10.1093/infdis/jir850 PMID: 22275401
22. Andrews L, Andersen RF, Webster D, Dunachie S, Walther RM, Bejon P, et al. (2005) Quantitative realtime polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg 73: 191-198. PMID: 16014857
23. Gaye O, Babou I, Faye O, Fall A, Molez JF, Bah IB, et al. (1993) [Malaria morbidity and therapeutic efficacy of antimalarials. Study conducted in the Dakar region]. Med Trop (Mars) 53: 479-485.
24. Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, et al. (2011) Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Molecular therapy: the journal of the American Society of Gene Therapy 19: 2269-2276.
25. Nebie I, Edwards NJ, Tiono AB, Ewer KJ, Sanou GS, Soulama I, et al. (2014) Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors. Clinical and vaccine immunology: CVI 21: 901-903. doi: 10.1128/CVI. 00723-13 PMID: 24739980
26. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, et al. (2013) DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 8: e55571. doi: 10.1371/journal.pone.0055571 PMID: 23457473
27. Hanke T, McMichael AJ, Dennis MJ, Sharpe SA, Powell LA, McLoughlin L, et al. (2005) Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 23: 1507-1514. doi: 10.1016/j.vaccine.2004.08.050 PMID: 15670887
28. Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, et al. (2006) Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346: 394-401. doi: 10.1016/j.virol.2005.10.042 PMID: 16356525
29. Top FH Jr., Buescher EL, Bancroft WH, Russell PK (1971) Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis 124: 155-160. PMID: 4330998
30. Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, et al. (2002) Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol 76: 2667-2675. doi: 10.1128/JVI.76.6.2667-2675.2002 PMID: 11861833
31. Longley RJ, Salman AM, Cottingham MG, Ewer K, Janse CJ, Khan SM, et al. (2015) Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Sci Rep 5: 11820. doi: 10.1038/srep11820 PMID: 26139288
32. Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, et al. (2016) Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. J Infect Dis 214: 772-781. doi: 10.1093/infdis/jiw244 PMID: 27307573